Decision to list haemodialysis equipment and products supplied by Nipro Australia Pty Limited
We are pleased to announce the approval of a listing agreement with Nipro Australia Pty Limited (“Nipro”) for the supply of haemodialysis equipment and products to DHBs.
What we’re doing
In summary this will result in:
- Nipro’s products being listed in Part III of Section H of the Pharmaceutical Schedule for 1 December 2020 under a national agreement that all DHBs may purchase under (“Agreement”); and
- DHBs being able to continue to purchase other suppliers’ brands of haemodialysis equipment and products.
Any changes to the original proposal?
This decision was subject to a consultation letter dated 13 October 2020.
There were no changes made to the Agreement as a result of the consultation feedback.
Who we think will be most interested
- DHB Staff
- Haemodialysis staff
- Procurement managers
- Suppliers and wholesalers
Details about this decision
In February 2018, PHARMAC issued a Request for Proposal (“RFP”) for haemodialysis products for non-exclusive national agreements for listing on the Pharmaceutical Schedule.
After completing the RFP evaluation processes, and consulting on the provisional Agreement reached with Nipro, PHARMAC has decided to list Nipro’s medical devices in Part III of Section H of the Pharmaceutical Schedule from 1 December 2020.
The list of products will be available on PHARMAC’s website from 1 December 2020, in both PDF and Excel spreadsheet formats.
DHBs can continue to choose which haemodialysis products they purchase, including those from other suppliers. DHBs that purchase haemodialysis products from Nipro must do so under the terms and conditions, including pricing, in the Agreement from 1 December 2020.
The Agreement includes terms and conditions for training and education to be provided by Nipro on the appropriate use of its products, which is to be provided at times as agreed with individual DHBs.
Our response to what you told us
We appreciate the time people took to respond to this consultation.
A summary of the main themes raised in feedback and our responses to the feedback are set out below:
Advised that no technical or resource impacts were anticipated as a result of this Agreement.
Support and endorse the proposal as it is not for sole supply of haemodialysis products.
If you have any questions about this decision, you can email us at firstname.lastname@example.org; or call our toll free number (9 am to 5 pm, Monday to Friday) on 0800 66 00 50.